阿昔洛韦联合人免疫球蛋白用于小儿EB病毒感染的临床疗效及安全性分析  

Clinical efficacy and safety of acyclovir combined with human immunoglobulin in children with EB virus infection

作　　者：戚艳 林聪聪 Qi Yan;Lin Congcong(Department of Pediatircs,Weihai Municipal Hospital,Weihai,Shandong 264200,China)

机构地区：[1]山东省威海市立医院,山东威海264200

出　　处：《首都食品与医药》2022年第19期72-74,共3页Capital Food Medicine

摘　　要：目的探讨小儿EB病毒感染应用阿昔洛韦联合人免疫球蛋白治疗的效果及安全性.方法纳入对象为山东省威海市立医院收治的EB病毒感染患儿178例,时间段为2018年4月-2022年2月,随机分两组,每组各89例.对照组患儿给予阿昔洛韦治疗,观察组患儿采用阿昔洛韦联合人免疫球蛋白治疗,比较两组的治疗效果.结果观察组的扁桃体肿大时间、住院时间、退热时间及咽痛时间,均短于对照组,差异有统计学意义(P<0.05).观察组的治疗总有效率为97.75%(87/89),高于对照组的74.16%(66/89),差异有统计学意义(P<0.05).治疗后,组间炎性因子水平比较,两组均比治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05).结论EB病毒感染患儿应用阿昔洛韦联合人免疫球蛋白治疗,效果确切.Objective To investigate the effect and safety of acyclovir combined with human immunoglobulin in the treatment of EB virus infection in children.Methods 178 children with EB virus infection treated in our hospital from April 2018 to February 2022 were randomly divided into two groups with 89 cases in each group.The children in the control group were treated with acyclovir,and the children in the observation group were treated with acyclovir combined with human immunoglobulin.The therapeutic effects of the two groups were compared.Results The time of tonsil enlargement,hospital stay.fever relief and pharyngeal pain in the observation group were shorter than those in the control group(P<0.05).The total effective rate of the ohservation group was 97.75%(87/89).which was higher than 74.16%(66/89)in the control group(P<0.05).After treatment,the levels of inflammatory factors in the two groups were lower than those before treatment,and the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conc lusion The acyclovir combined with human immunoglobulin is effective in the treatment of children with EB virus infection.

关 键 词：人免疫球蛋白 EB病毒 阿昔洛韦 安全性 

分 类 号：R725[医药卫生—儿科]